Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says
(18h)
Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout
(19h)
Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
(20h)
Cardiac medtech HeartBeam drops CEO in restructuring aimed at global ECG platform push
(21h)
Chutes & Ladders—EMD Serono taps in new commercial strategy head
(1d)
BioPharma Dive
At BIO, tension over China biotech deal regulation looms
(17h)
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
(19h)
On second try, Acadia drug gets nod from European regulators
(19h)
Remix to go public in reverse merger with once high-flying Passage Bio
(1d)
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
(1d)
Endpoints News
FDA approves Viridian eye drug, stoking competition with Amgen's Tepezza
(9h)
FDA advisory panels are back, with new meetings for Replimune, Capricor
(14h)
Akeso pushes back on ASCO questioning of lung cancer drug
(17h)
EU probes Sanofi for alleged smear campaign against rival flu vaccine
(17h)
Lycia raises $75M for food allergy and Graves’ disease
(18h)
BioSpace
Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy
(13h)
BIO 2026: Making biotech IPOs great again and the forgotten pharma antitrust review
(19h)
The hidden cost of FDA unpredictability
(19h)
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
(20h)
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
(20h)
STAT News
BIO 2026: AI, federal policy impacts, and general vibes
(15h)
Up and down the ladder: The latest comings and goings
(17h)
988’s LGBTQ+ hotline to relaunch this year. But the group that helped start it might be excluded
(18h)
Embryo editing advances reignite ethical debates
(19h)
We’re reading about a bill to overhaul the 340B program, a new FDA commish candidate, and more
(19h)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(18h)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1w)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(1mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Drug Channels
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(22h)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(4d)
The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy
(1w)
Drug Channels News Roundup, Mid-June 2026: Biosimilar Development Barriers, Hospital Specialty Pharmacy Growth, Medicaid Incentives, Drug Pricing Tradeoffs, and the Prescription-Filling Process
(1w)
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs
(1w)
European Biotechnology Magazine
ProQR validates RNA editing platform and raises $59.2m
(1d)
Recordati secures ex-U.S. rights to Ionis’ Alexander disease therapy
(1d)
ADC Therapeutics cuts 17% of staff after safety setback
(2d)
Novartis signs up to $1.9bn deal to tap Antares’ undruggable-target engine
(2d)
Leyden Labs adds €40m for intranasal flu prevention
(2d)
Drug Hunter
May 2026
(13h)
MRTX1719
(1d)
cleminorexton
(2d)
fluoxetine
(3d)
An ADC Primer for Medicinal Chemists
(4d)
Labiotech.EU
“It’s time to Act”: EU biotech to undergo major changes
(19h)
De-risking neurology drug development with better mouse models
(1d)
How human-first datasets are reshaping AI drug discovery
(2d)
Roche, a company built on oncology and diagnostics reinventing its pipeline
(2d)
Bronchiectasis treatment after brensocatib: where the field goes next
(3d)
Bio IT World
The Spatial Biology Bottleneck: Why AI Models Fail on Complex Tissue & What Actually Fixes It
(1d)
Every Microbiome Tells a Changeable, Computable Story
(3d)
Notes from the Trenches: A Computational Biologist’s View of Drug Discovery’s Digital Revolution
(4d)
AI Readiness in Pharma – Getting the Foundation Right
(1w)
AI Readiness in Pharma – Getting the Foundation Right
(1w)
GEN News
Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Disease Biologics
(13h)
Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality
(16h)
Intravesical CAR T-Cell Therapy Reduces Bladder Cancer Growth in Preclinical Model
(16h)
Nipah and Hendra Viruses: Antibody Cocktail Provides Complete Protection in Hamster Model
(17h)
Circio’s circVec and Tcelltech’s nanoSMAR Technologies Combined to Generate Nextgen In vivo CAR-T and TCR-T Cells
(20h)
Cure Today
Without Cancer I Am Practicing Self-Care
(1d)
FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer
(2d)
The Whole Person: How Susan Yaguda Is Redefining Cancer Care
(2d)
FDA Approves Ibrance Combo for Maintenance Treatment of HR-Positive, HER2-Positive Metastatic Breast Cancer
(2d)
Living With Cancer: What the Mariana Trench and Cancer Have in Common
(2d)
Contract Pharma
Reducing Risk in Pharma Product Transfers
(15h)
Adragos Pharma Kawagoe, Towa Pharmaceutical Ink Strategic Supply Pact
(17h)
AI in Biologics CDMO Workflows: A BIO Conversation with Lonza
(17h)
The Friday Brief for June 26, 2026: BIO 2026 Recap
(18h)
Enzene Premieres Nex Partnership Program at BIO 2026
(1d)
Pharma Times
Racura treats first patient in phase 1 HARNESS‑1 lung cancer trial
(2d)
NICE recommends MSD’s pembrolizumab for locally advanced cervical cancer
(2d)
Lundbeck to present new Vyepti and bocunebart data at EAN 2026
(2d)
Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
(3d)
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC
(4d)
Medcity News
What Is AI Getting Right — and Wrong — in Healthcare’s Revenue Cycle?
(1w)
KFF: Insurer Participation in ACA Marketplaces Is Down
(1w)
FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
(1w)
Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards
(1w)
The Human Behind the Machine: Why Healthcare Must Resist the Rush To Automate
(1w)
Chemical & Engineering News
Supreme Court sides with Bayer in landmark pesticide-labeling case
(13h)
A new method measures PFAS-based microplastics
(15h)
Policy Watch: HHS moves to keep more drug trials in the US
(16h)
Ancient Martian rocks preserve complex organic carbon
(17h)
Membrane-based separations for more efficient crude oil refining
(19h)
The Pharma Letter
Why has the need in gMG become so severe, and how has understanding evolved?
(16h)
EC opens formal antitrust investigation on Sanofi
(16h)
June 2026 batch of EMA/CHMP recommendations
(16h)
Elixirgen and Nippon Shinyaku ink option agreement on DMD
(19h)
EC approves Inaqovi combination for AML patients ineligible for intensive chemotherapy
(19h)
Targeted Oncology
NCCN Guidelines Recommend ctDNA-MRD Testing in MIBC Care
(1d)
Emerging Evidence for Earlier Intervention in Low-Risk Polycythemia Vera
(2d)
Why Many Oncologists Still Reach for G-CSF Over Trilaciclib in ES-SCLC
(2d)
FDA Approves Sacituzumab Govitecan for First-Line TNBC Treatment
(2d)
KOMET-007: Bringing Menin Inhibition Into Frontline AML Care
(2d)
MedWatch
Hims & Hers poised to benefit as insurers pull back on weight-loss drug coverage
(20h)
Demant on track for best quarter since the turn of the millennium
(21h)
GN Hearing CFO to join Danish shipping company
(22h)
US biotech index hits record high, Danske Bank cites several drivers
(23h)
Removing gender and photos from applications led Gubra to gender equality in management
(23h)
In The Pipeline
Speaking Up: Who Is, and Who Isn't
(11h)
Antibody-Drug Conjugates: Not Quite Worked Out Yet
(1d)
Here's a Ligand, Go Design a Protein
(2d)
Machine-Learning Mass Spec Data: Hmmm
(4d)
Covid-19 Vaccinations and the Heart
(2w)
Pharmaphorum
Sanofi faces EU investigation over flu shot marketing
(21h)
Moderna shows in vivo CAR-T hand in R&D update
(22h)
Obesity is rising fastest in young adults in England
(1d)
Merck buys life sciences firm Bio-techne in $11.3bn deal
(1d)
Hub-and-spoke firm Osanni raises $190m, and other financings
(1d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1w)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1w)
Webinar: Learn how to accelerate the early stages of drug discovery
(1w)
Therapy enables 89% survival rate in myeloma patients
(1w)
Ulcerative colitis treatment shows best-in-class potential
(1w)
HIT Consultant
KLAS Arch Collaborative Releases Clinician EHR Experience 2026 Impact Report
(18h)
Hera Raises $27M to Scale AI-Powered Senior Care Coordination
(18h)
ZS Impact Institute Releases 2026 Future of Health Report: AI and the Consumer-Led Care Revolution
(19h)
Hurone AI Licenses Mayo Clinic’s HOUSES Technology to Scale Personalized Cancer Navigation
(19h)
AMGA 2026 Survey: Provider Compensation Rises 4.3% as Medical Groups Face Sustainability Warning
(19h)
Insights: Pink Sheet
US Pushing Foreign Countries To Pay More For Drugs: Will It Help Americans?
(10h)
BsUFA IV: Money Can’t Buy Industry Reference Product Exclusivity Determinations
(12h)
US FDA Adcomm Will Review Formerly Rejected Capricor, Replimune Regenerative Medicines
(14h)
Trump Nominates Medicare Director, HHS Power Broker Chris Klomp For Deputy Secretary
(14h)
Pink Sheet Podcast: US FDA’s New Guidance On One-Trial Efficacy Standard And IND Reform Pilot
(16h)
BioXconomy
AI cannot fix oncology drug discovery when preclinical models fail to reflect patient tumor biology
(12h)
Saudi drug authority expands US partnerships
(18h)
Clinilabs partners with Rutgers clinical research training
(20h)
Boundless Bio merges with Serapha Bio in $230m deal
(21h)
UK government advisors recommend mAb for type I diabetes treatment
(21h)
BioCentury
Immunic tests Nurr1 to push beyond MS’s inflammation ceiling
(7h)
House committee to vote on China investment and in-licensing restrictions
(9h)
Definium’s $805M offering leads follow-on quartet: Public Equity Report
(9h)
CHMP joins FDA in challenging Tavneos’ approval basis
(10h)
Upcoming FDA adcomms will test post-Makary independence
(11h)
SCRIP
Viridian’s Lumvoa Puts Pressure On Amgen’s Tepezza In TED
(9h)
BIO 2026: Deals Are Surging Even As Chinese Competition And MFN Concerns Linger
(10h)
Callio Makes The Case For Dual-Payload ADCs
(13h)
Pfizer Discontinues Vizimpro In US Amid Oncologist Preference Shift
(17h)
Encouraging Signs For Revolution’s Pancreatic Cancer Combinations
(17h)